CD19-directed CAR T-cell therapy can lead to sustained remission in DLBCL, but relapse is common, affecting up to 60% of patients. Epcoritamab, a bispecific T-cell engager, may enhance CAR T-cell ...

Relapse isn’t a failure. It’s a signal. It tells us that something deeper is still driving our old behaviors. For decades, I’ve studied the science of addiction, relapse, and behavior change through ...

A young man in recovery from addiction once gave me his perspective on the painful consequences of relapse: “It’s not the relapse that troubles me,” he said. “It’s the self-beating that comes ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapse after ...